clinicaladvisor.com

American Gastroenterological Association Releases First “Living” Guideline for Moderate-to-Severe Ulcerative Colitis

AGA living guideline recommends patients start advanced therapies early in their disease course rather than gradual step-up treatment approach. “Since the first biologic treatment for ulcerative ...
Morningstar

MRM Health Secures FDA IND Clearance to Launch its Phase 2b Trial of MH002 in Mild-to-Moderate Ulcerative Colitis

MH002 is currently the most advanced Live Biotherapeutic Product (LBP) based on a rationally-designed combination of disease specific bacteria (microbial consortia), for the treatment of inflammatory ...
Seeking Alpha

Morphic to Present Positive EMERALD-1 Phase 2a Data for MORF-057 in Patients with Moderate to Severe Ulcerative Colitis in Abstract for UEGW 2023

-PK/PD confirm results seen in healthy volunteer studies, with median RO >99% and saturation achieved early and sustained at week 12- WALTHAM, Mass., Sept. 22, 2023 (GLOBE NEWSWIRE) -- Morphic ...
Morningstar

Ferring Demonstrates Effectiveness of a Treat-to-Target Approach in Mild-to-Moderate Ulcerative Colitis in First Major Study

Ferring Pharmaceuticals today announces results from the OPTIMISE study showing the first real-world evidence of the effectiveness of a treat-to-target (T2T) approach based on faecal calprotectin (FC) ...
Nasdaq

Abivax Reports Positive Interim Efficacy and Safety Analysis of Once-Daily 25mg Obefazimod in Moderate to Severe Ulcerative Colitis Patients After 2-Years of Open-Label Maintenance

Abivax Reports Positive Interim Efficacy and Safety Analysis of Once-Daily 25mg Obefazimod in Moderate to Severe Ulcerative Colitis Patients After 2-Years of Open-Label Maintenance Patients treated ...
Seeking Alpha

Abivax Announces Positive Phase 3 Results from Both ABTECT 8-Week Induction Trials Investigating Obefazimod, its First-in-Class Oral miR-124 Enhancer, in Moderate to Severely ...

50 mg once-daily dose of obefazimod led to a compelling pooled 16.4% (p<0.0001) placebo-adjusted clinical remission rate at Week 8 in the ABTECT-1 (Study 105) and ABTECT-2 (Study 106) trials.
clinicaladvisor.com

Progression of Dysplasia in a Young Man with Ulcerative Colitis: A Case Study

Credit: Getty Images A 29-year-old man undergoes a total proctocolectomy with end-to-end ileostomy after 2 years of surveillance for ulcerative colitis. A 29-year-old White man presents in May 2023 ...
EurekAlert!

First American Gastroenterological Association living guideline for moderate-to-severe ulcerative colitis

Bethesda, MD (Nov. 15, 2024) — The American Gastroenterological Association (AGA) has released a new clinical guideline on the pharmacological management of moderate-to-severe ulcerative colitis, ...